Screener
Celldex Therapeutics CLDX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $14,675 | $1,180 |
| Accrued expenses | 43,863 | 47,029 |
| Current portion of operating lease liabilities | 1,557 | 1,552 |
| Current portion of other long-term liabilities | 1,230 | 1,230 |
| Total current liabilities | 61,325 | 50,991 |
| Long-term portion of operating lease liabilities | 3,347 | 784 |
| Other long-term liabilities | 3,113 | 4,043 |
| Total liabilities | 67,785 | 55,818 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's accrued expenses?
- Celldex Therapeutics (CLDX) reported accrued expenses of $1.23M in Q2 2026.
- How has Celldex Therapeutics's accrued expenses changed year-over-year?
- Celldex Therapeutics's accrued expenses increased by 32.3% year-over-year, from $930K to $1.23M.
- What is the long-term trend for Celldex Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accrued expenses has grown at a -18.3% compound annual growth rate (CAGR), from $3.37M to $1.23M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Celldex Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude